ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2024-1-134-143ssmu-5536Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESВульвовагинальная атрофия: современные методы диагностики и лечения (обзор литературы)Vulvovaginal atrophy: current methods of diagnosis and treatmenthttps://orcid.org/0000-0001-5256-843XЗайнетдиноваЛ. Ф.ZainetdinovaL. F.

Зайнетдинова Лариса Фоатовна – д-р мед. наук, доцент, профессор кафедры акушерства и гинекологии

454092, г. Челябинск, ул. Воровского, 64

64, Vorovskogo Str., Chelyabinsk, 454092

sea-gull6@yandex.ruhttps://orcid.org/0000-0002-7884-9675ТелешеваЛ. Ф.TeleshevaL. F.

Телешева Лариса Федоровна –д-р мед. наук, профессор, профессор кафедры микробиологии, вирусологии, иммунологии

454092, г. Челябинск, ул. Воровского, 64

64, Vorovskogo Str., Chelyabinsk, 454092

teleshevalarisa@mail.ruhttps://orcid.org/0009-0000-5633-6951МедведевБ. И.MedvedevB. I.

Медведев Борис Иванович –д-р мед. наук, профессор, профессор кафедры акушерства и гинекологии

454092, г. Челябинск, ул. Воровского, 64

64, Vorovskogo Str., Chelyabinsk, 454092

borismedvedev423@gmail.comХахулинаВ. В.KhakhulinaV. V.

Хахулина Виктория Владимировна – преподаватель, кафедра акушерства и гинекологии

454092, г. Челябинск, ул. Воровского, 64

64, Vorovskogo Str., Chelyabinsk, 454092

viktoriahahulina95@mail.ruЮжно-Уральский государственный медицинский университет (ЮУГМУ)РоссияSouth Ural State Medical UniversityRussian Federation202411042024231134143Copyright © Зайнетдинова Л.Ф., Телешева Л.Ф., Медведев Б.И., Хахулина В.В., 20242024Зайнетдинова Л.Ф., Телешева Л.Ф., Медведев Б.И., Хахулина В.В.Zainetdinova L.F., Telesheva L.F., Medvedev B.I., Khakhulina V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/5536

Целью публикации является обзор современных методов диагностики и лечения вульво-вагинальной атрофии (ВВА), которая является одним из проявлений генитоуринарного менопаузального синдрома у женщин в перии постменопаузе.

Материалы и методы

Материалы и методы. Проведен обзор отечественных и зарубежных источников, посвященных распространенности, диагностике и методам лечения ВВА.

Результаты

Результаты. В отличие от вазомоторных симптомов, ВВА прогрессирует с возрастом, вызывая значительное нарушение качества жизни женщин. Симптомы, как правило, начинают беспокоить пациенток в перименопаузе, но их частота и выраженность значительно возрастают в постменопаузе. Диагностика ВВА может представлять некоторые трудности, так как многие женщины воспринимают свое состояние как естественное проявление старения организма и не обращаются за медицинской помощью. В настоящее время предложены медикаментозные и немедикаментозные методы лечения ВВА, каждый из которых имеет свои особенности, показания и противопоказания. Однако безопасность и эффективность некоторых из них полностью не доказана.

Заключение

Заключение. Вульво-вагинальная атрофия часто встречается у женщин перии постменопаузального возраста. Современные аспекты диагностики и лечения данной патологии позволяют значительно повысить качество жизни пациенток с симптомами ВВА, однако необходимы дальнейшие исследования для подтверждения безопасности предлагаемых методов лечения и поиск новых.

Aim

Aim. To review modern methods of diagnosis and treatment of vulvovaginal atrophy (VVA), which is one of the manifestations of genitourinary syndrome of menopause in periand postmenopausal women.

Materials and methods

Materials and methods. A review of domestic and foreign literature on the prevalence and modern methods of diagnosis and treatment of VVA was carried out.

Results

Results. Unlike vasomotor symptoms, VVA progresses with age, causing a significant impairment in women’s quality of life. Symptoms usually begin to bother perimenopausal patients, but their frequency and severity increase significantly in postmenopausal women. Diagnosis of VVA can present some difficulties, as many women perceive their condition as a natural manifestation of aging and do not seek medical care. Currently, drug and non-drug therapies for VVA have been proposed, each of which has its own characteristics, indications, and contraindications. However, the safety and effectiveness of some of them have not been fully proven.

Conclusion

Conclusion. VVA is common in periand postmenopausal women. Modern aspects of the diagnosis and treatment of this pathology can significantly improve the quality of life of patients with VVA symptoms. However, further research is needed to confirm safety of the proposed treatment methods, and search for new techniques is required.

вульво-вагинальная атрофиягенитоуринарный менопаузальный синдромперии постменопаузаvulvovaginal atrophygenitourinary syndrome of menopauseperiand postmenopauseReferencesЮренева С.В., Ермакова Е.И., Глазунова А.В. Диагностика и терапия генитоуринарного менопаузального синдрома у пациенток в пери- и постменопаузе (краткие клинические рекомендации). Акушерство и гинекология. 2016;(5):138– 144. DOI: 10.18565/aig.2016.5.138-144.Юренева С.В., Ермакова Е.И., Глазунова А.В. Диагностика и терапия генитоуринарного менопаузального синдрома у пациенток в пери- и постменопаузе (краткие клинические рекомендации). Акушерство и гинекология. 2016;(5):138– 144. DOI: 10.18565/aig.2016.5.138-144.Brodman K.F. Genitourinary syndrome of menopause. in: mount sinai expert guides: obstetrics and gynecology (ed); R. Sperling. New York, NY, USA: John Wiley & Sons Ltd, 2020:210–217.Brodman K.F. Genitourinary syndrome of menopause. in: mount sinai expert guides: obstetrics and gynecology (ed); R. Sperling. New York, NY, USA: John Wiley & Sons Ltd, 2020:210–217.Sinha A., Ewies A.A.A. Non-hormonal topical treatment of vul-vovaginal atrophy: an up-to-date overview. Climacteric. 2013;16:305–331. DOI: 10.3109/13697137.2012.756466.Sinha A., Ewies A.A.A. Non-hormonal topical treatment of vul-vovaginal atrophy: an up-to-date overview. Climacteric. 2013;16:305–331. DOI: 10.3109/13697137.2012.756466.Palma F., Volpe A., Villa P., Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2016;83:40–44. DOI: 10.1016/j.maturitas.2015.09.001.Palma F., Volpe A., Villa P., Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas. 2016;83:40–44. DOI: 10.1016/j.maturitas.2015.09.001.Kingsber S.A., Krychman M., Graham S., Bernick B., Mirkin S. The Women’s EMPOWER Survey: Identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J. Sex Med. 2017;14:413–424. DOI: 10.1016/j.jsxm.2017.01.010.Kingsber S.A., Krychman M., Graham S., Bernick B., Mirkin S. The Women’s EMPOWER Survey: Identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J. Sex Med. 2017;14:413–424. DOI: 10.1016/j.jsxm.2017.01.010.Nappi R.E., Seracchioli R., Salvatore S., Cagnacci A., Di Paolantonio T., Busacca M. Impact of vulvovaginal atrophy of menopause: Prevalence and symptoms in Italian women according to the EVES study. Gynecol. Endocrinol. 2019;35:453– 459. DOI: 10.1080/09513590.2018.1563883.Nappi R.E., Seracchioli R., Salvatore S., Cagnacci A., Di Paolantonio T., Busacca M. Impact of vulvovaginal atrophy of menopause: Prevalence and symptoms in Italian women according to the EVES study. Gynecol. Endocrinol. 2019;35:453– 459. DOI: 10.1080/09513590.2018.1563883.Moral E., Delgado J.L., Carmona F., Caballero B., Guillán C., González P.M. et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21:167–173. DOI: 10.1080/13697137.2017.1421921.Moral E., Delgado J.L., Carmona F., Caballero B., Guillán C., González P.M. et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21:167–173. DOI: 10.1080/13697137.2017.1421921.Cagnacci A., Xholli A., Sclauzero M., Venier M., Palma F., Gambacciani M. Vaginal atrophy across the menopausal age: Results from the ANGEL study. Climacteric. 2019;22:85–89. DOI: 10.1080/13697137.2018.1529748.Cagnacci A., Xholli A., Sclauzero M., Venier M., Palma F., Gambacciani M. Vaginal atrophy across the menopausal age: Results from the ANGEL study. Climacteric. 2019;22:85–89. DOI: 10.1080/13697137.2018.1529748.Gandhi J., Chen A., Dagur G., Suh Y., Smith N., Cali B. et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am. J. Obstet. Gynecol. 2016;215:704–711. DOI: 10.1016/j.ajog.2016.07.045.Gandhi J., Chen A., Dagur G., Suh Y., Smith N., Cali B. et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am. J. Obstet. Gynecol. 2016;215:704–711. DOI: 10.1016/j.ajog.2016.07.045.Alvisi S., Gava G., Orsili I., Giacomelli G., Baldassarre M., Seracchioli R. et al. Review: vaginal health in menopausal women. Medicina. 2019;55:615. DOI: 10.3390/medicina55100615.Alvisi S., Gava G., Orsili I., Giacomelli G., Baldassarre M., Seracchioli R. et al. Review: vaginal health in menopausal women. Medicina. 2019;55:615. DOI: 10.3390/medicina55100615.Levine K., Williams R., Hartmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15:661–666. DOI: 10.1097/gme.0b013e31815a5168.Levine K., Williams R., Hartmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15:661–666. DOI: 10.1097/gme.0b013e31815a5168.Da Silva A.S., Baines G., Araklitis G., Robinson D., Cardozo L. Modern management of genitourinary syndrome of menopause. Fac. Rev. 2021;10:25. DOI: 10.12703/r/10-25.Da Silva A.S., Baines G., Araklitis G., Robinson D., Cardozo L. Modern management of genitourinary syndrome of menopause. Fac. Rev. 2021;10:25. DOI: 10.12703/r/10-25.Santoro N., Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J. Sex Med. 2009;6:2133–2142. DOI: 10.1111/j.1743-6109.2009.01335.x.Santoro N., Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J. Sex Med. 2009;6:2133–2142. DOI: 10.1111/j.1743-6109.2009.01335.x.Jannini E.A., Nappi R.E. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med. Rev. 2018;6:384–395. DOI: 10.1016/j.sxmr.2017.11.002.Jannini E.A., Nappi R.E. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med. Rev. 2018;6:384–395. DOI: 10.1016/j.sxmr.2017.11.002.Miller E.A., Beasley D.E., Dunn R.R., Archie E.A. Lactobacilli dominance and vaginal pH: Why is the human vaginal microbiome unique? Front. Microbiol. 2016;7:1936. DOI: 10.3389/fmicb.2016.01936.Miller E.A., Beasley D.E., Dunn R.R., Archie E.A. Lactobacilli dominance and vaginal pH: Why is the human vaginal microbiome unique? Front. Microbiol. 2016;7:1936. DOI: 10.3389/fmicb.2016.01936.Briggs P. Genitourinary syndrome of menopause. Post. Reprod. Health. 2020;26(2):111–114. DOI: 10.1177/2053369119884144.Briggs P. Genitourinary syndrome of menopause. Post. Reprod. Health. 2020;26(2):111–114. DOI: 10.1177/2053369119884144.Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–1068. DOI: 10.1097/GME.0000000000000329.Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–1068. DOI: 10.1097/GME.0000000000000329.Nappi R.E., Palacios S., Panay N., Particco M., Krychman M.L. Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197. DOI: 10.3109/13697137.2015.1107039.Nappi R.E., Palacios S., Panay N., Particco M., Krychman M.L. Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197. DOI: 10.3109/13697137.2015.1107039.Kim H., Kang S.Y., Chung Y.J., Kim J.H., Kim M.R. The recent review of the genitourinary syndrome of menopause. J. Menopausal. Med. 2015;21:65–71. DOI: 10.6118/jmm.2015.21.2.65.Kim H., Kang S.Y., Chung Y.J., Kim J.H., Kim M.R. The recent review of the genitourinary syndrome of menopause. J. Menopausal. Med. 2015;21:65–71. DOI: 10.6118/jmm.2015.21.2.65.Briggs P. Genitourinary syndrome of menopause. Post. Reproductive Health. 2020;26(2):111–114. DOI: 10.1177/2053369119884144.Briggs P. Genitourinary syndrome of menopause. Post. Reproductive Health. 2020;26(2):111–114. DOI: 10.1177/2053369119884144.Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front. Microbiol. 2019;10:193. DOI: 10.3389/fmicb.2019.00193.Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front. Microbiol. 2019;10:193. DOI: 10.3389/fmicb.2019.00193.Stika C.S. Atrophic vaginitis. Dermatol. Ther. 2010;23(5):514– 522. DOI: 10.1111/j.1529-8019.2010.01354.x.Stika C.S. Atrophic vaginitis. Dermatol. Ther. 2010;23(5):514– 522. DOI: 10.1111/j.1529-8019.2010.01354.x.Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б. (ред.) Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа, 2017:1008.Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б. (ред.) Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа, 2017:1008.Овсянникова Т.В., Макаров И.О., Боровкова Е.И., Куликов И.А. Местная терапия урогенитальных нарушений в пери- и постменопаузе. Акушерство, гинекология и репродукция. 2010;4(3):25–28.Овсянникова Т.В., Макаров И.О., Боровкова Е.И., Куликов И.А. Местная терапия урогенитальных нарушений в пери- и постменопаузе. Акушерство, гинекология и репродукция. 2010;4(3):25–28.Rees M., Perez-Lopez F.R., Ceasu I., Depypere H., Erel T., Lambrinoudaki I. et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal atrophy. Maturitas. 2012;73(2):171–174. DOI: 10.1016/j.maturitas.2012.06.009.Rees M., Perez-Lopez F.R., Ceasu I., Depypere H., Erel T., Lambrinoudaki I. et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal atrophy. Maturitas. 2012;73(2):171–174. DOI: 10.1016/j.maturitas.2012.06.009.Hummelen R., Macklaim J.M., Bisanz J.E., Hammond J.A., McMillan A., Vongsa R. et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6:e26602. DOI: 10.1371/journal.pone.0026602.Hummelen R., Macklaim J.M., Bisanz J.E., Hammond J.A., McMillan A., Vongsa R. et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6:e26602. DOI: 10.1371/journal.pone.0026602.Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21:450–458. DOI: 10.1097/GME.0b013e3182a4690b.Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014;21:450–458. DOI: 10.1097/GME.0b013e3182a4690b.Shen J., Song N., Williams C.J., Brown C.J., Yan Z., Xu C., Forney L.J. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci. Rep. 2016;6:24380. DOI: 10.1038/srep24380.Shen J., Song N., Williams C.J., Brown C.J., Yan Z., Xu C., Forney L.J. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci. Rep. 2016;6:24380. DOI: 10.1038/srep24380.Аполихина И.А., Горбунова Е.А. Клинико-морфологические аспекты вульвовагинальной атрофии. Медицинский совет. 2014;(9):110–117.Аполихина И.А., Горбунова Е.А. Клинико-морфологические аспекты вульвовагинальной атрофии. Медицинский совет. 2014;(9):110–117.Hess R., Austin R.M., Dillon S., Chang C.C., Ness R.B. Vaginal maturation index self-sample collection in mid-life women: Acceptability and correlation with physician-collected samples. Menopause. 2008;15:726–729. DOI: 10.1097/gme.0b013e31816c5541.Hess R., Austin R.M., Dillon S., Chang C.C., Ness R.B. Vaginal maturation index self-sample collection in mid-life women: Acceptability and correlation with physician-collected samples. Menopause. 2008;15:726–729. DOI: 10.1097/gme.0b013e31816c5541.Bachmann G. Urogenital ageing: An old problem newly recognized. Maturitas. 1995;22:S1–S5. DOI: 10.1016/0378-5122(95)00956-6.Bachmann G. Urogenital ageing: An old problem newly recognized. Maturitas. 1995;22:S1–S5. DOI: 10.1016/0378-5122(95)00956-6.Fernandez-Alonso A.M., Cuerva M.J., Chedraui P., Pérez-López F.R. Screening and management of female sexual dysfunction during the second half of life. In: Pérez-López F.R. (ed.). Postmenopausal diseases and disorders. Switzerland: Springer International Publishing, 2019:165–185.Fernandez-Alonso A.M., Cuerva M.J., Chedraui P., Pérez-López F.R. Screening and management of female sexual dysfunction during the second half of life. In: Pérez-López F.R. (ed.). Postmenopausal diseases and disorders. Switzerland: Springer International Publishing, 2019:165–185.Erekson E.A., Yip S.O., Wedderburn T.S., Martin D.K., Li F.-Y., Choi J.N. et al. The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013;20:973– 979. DOI: 10.1097/GME.0b013e318282600b.Erekson E.A., Yip S.O., Wedderburn T.S., Martin D.K., Li F.-Y., Choi J.N. et al. The vulvovaginal symptoms questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013;20:973– 979. DOI: 10.1097/GME.0b013e318282600b.Huang A.J., Gregorich S.E., Kuppermann M., Nakagawa S., Van Den Eeden S.K., Brown J.C. et al. Daily impact of the vaginal aging questionnaire: a multivariate measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015;22(2):144–154. DOI: 10.1097/GME.0000000000000281.Huang A.J., Gregorich S.E., Kuppermann M., Nakagawa S., Van Den Eeden S.K., Brown J.C. et al. Daily impact of the vaginal aging questionnaire: a multivariate measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015;22(2):144–154. DOI: 10.1097/GME.0000000000000281.Eaton A.A., Baser R.E., Seidel B., Stabile C., Canty J.P., Goldfrank D.J. et al. Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors. J. Sex Med. 2017;14(1):144–151. DOI: 10.1016/j.jsxm.2016.11.317.Eaton A.A., Baser R.E., Seidel B., Stabile C., Canty J.P., Goldfrank D.J. et al. Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors. J. Sex Med. 2017;14(1):144–151. DOI: 10.1016/j.jsxm.2016.11.317.Alvisi S., Gava G., Orsili I., Giacomelli G., Baldassarre M., Seracchioli R. et al. Vaginal health in menopausal women. Medicina. 2019;55(10):615. DOI: 10.3390/medicina55100615.Alvisi S., Gava G., Orsili I., Giacomelli G., Baldassarre M., Seracchioli R. et al. Vaginal health in menopausal women. Medicina. 2019;55(10):615. DOI: 10.3390/medicina55100615.Angelou K., Grigoriadis T., Diakosavvas M., Zacharakis D., Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586. DOI: 10.7759/cureus.7586.Angelou K., Grigoriadis T., Diakosavvas M., Zacharakis D., Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586. DOI: 10.7759/cureus.7586.Mac Bride M.B., Rhodes D.J., Shuster L.T. Vulvovaginal atrophy. Mayo Clin. Proc. 2010;85:87–94. DOI: 10.4065/mcp.2009.0413.Mac Bride M.B., Rhodes D.J., Shuster L.T. Vulvovaginal atrophy. Mayo Clin. Proc. 2010;85:87–94. DOI: 10.4065/mcp.2009.0413.Прилепская В.Н. Генитоуринарный менопаузальный синдром: возможности эстриола. Гинекология. 2018;20(1):5– 8. DOI: 10.26442/2079-5696_20.1.5-8.Прилепская В.Н. Генитоуринарный менопаузальный синдром: возможности эстриола. Гинекология. 2018;20(1):5– 8. DOI: 10.26442/2079-5696_20.1.5-8.Panay N., Palacios S., Bruyniks N., Particco M., Nappi R.E. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55–61. DOI: 10.1016/j.maturitas.2019.03.013.Panay N., Palacios S., Bruyniks N., Particco M., Nappi R.E. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55–61. DOI: 10.1016/j.maturitas.2019.03.013.Nappi R.E., Biglia N., Cagnacci A., Di Carlo C., Luisi S., Paoletti A.M. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol. Endocrinol. 2016;32:602–606. DOI: 10.1080/09513590.2016.1183627.Nappi R.E., Biglia N., Cagnacci A., Di Carlo C., Luisi S., Paoletti A.M. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol. Endocrinol. 2016;32:602–606. DOI: 10.1080/09513590.2016.1183627.The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. DOI: 10.1097/GME.0000000000001609.The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. DOI: 10.1097/GME.0000000000001609.Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition? Review. Climacteric. 2016;19(2):151–161. DOI: 10.3109/13697137.2015.1124259.Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition? Review. Climacteric. 2016;19(2):151–161. DOI: 10.3109/13697137.2015.1124259.ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet. Gynecol. 2014;123(1):202–216. DOI: 10.1097/01.AOG.0000441353.20693.78.ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet. Gynecol. 2014;123(1):202–216. DOI: 10.1097/01.AOG.0000441353.20693.78.Salwowska N.M., Bebenek K.A., Żądło D.A., Wcisło-Dziadecka D.L. Physiochemical properties and application of hyaluronic acid: A systematic review. J. Cosmet. Dermatol. 2016;15(4):520–526. DOI: 10.1111/jocd.12237.Salwowska N.M., Bebenek K.A., Żądło D.A., Wcisło-Dziadecka D.L. Physiochemical properties and application of hyaluronic acid: A systematic review. J. Cosmet. Dermatol. 2016;15(4):520–526. DOI: 10.1111/jocd.12237.Mitchell C.M., Guthrie K.A., Larson J., Diem S., LaCroix A.Z., Caan B. et al. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women. Menopause. 2019;26(8):816–822. DOI: 10.1097/GME.0000000000001341.Mitchell C.M., Guthrie K.A., Larson J., Diem S., LaCroix A.Z., Caan B. et al. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women. Menopause. 2019;26(8):816–822. DOI: 10.1097/GME.0000000000001341.Шалина М.А., Лисянская М.В., Нестеров И.М. Современная терапия пациенток с вульвовагинальной атрофией в пери- и постменопаузе. (Опыт клинического применения). Российский вестник акушера-гинеколога. 2022;22(5):100– 103. DOI: 10.17116/rosakush202222051100.Шалина М.А., Лисянская М.В., Нестеров И.М. Современная терапия пациенток с вульвовагинальной атрофией в пери- и постменопаузе. (Опыт клинического применения). Российский вестник акушера-гинеколога. 2022;22(5):100– 103. DOI: 10.17116/rosakush202222051100.Татарова Н.А., Линде В.А., Гусев С.Н. Негормональная терапия генитоуринарного менопаузального синдрома. Вопросы гинекологии, акушерства и перинатологии. 2021;20(2):141–146. DOI: 10.20953/1726-1678-2021-2-141-146.Татарова Н.А., Линде В.А., Гусев С.Н. Негормональная терапия генитоуринарного менопаузального синдрома. Вопросы гинекологии, акушерства и перинатологии. 2021;20(2):141–146. DOI: 10.20953/1726-1678-2021-2-141-146.Тихомирова Е.В., Балан В.Е., Титченко Ю.П., Фомина-Нилова О.С. Возможности негормональной терапии пациенток с вульвовагинальной атрофией. Российский вестник акушера-гинеколога. 2020;20(4):58–64. DOI: 10.17116/rosakush20202004158.Тихомирова Е.В., Балан В.Е., Титченко Ю.П., Фомина-Нилова О.С. Возможности негормональной терапии пациенток с вульвовагинальной атрофией. Российский вестник акушера-гинеколога. 2020;20(4):58–64. DOI: 10.17116/rosakush20202004158.Пестрикова Т.Ю., Юрасова Е.А., Швеева М.А., Ковалева Т.Д. Персонифицированный подход к тактике ведения пациенток с атрофическим вульвовагинитом в постменопаузе. Российский вестник акушера-гинеколога. 2020;20(3):62–67. DOI: 10.17116/rosakush20202003162.Пестрикова Т.Ю., Юрасова Е.А., Швеева М.А., Ковалева Т.Д. Персонифицированный подход к тактике ведения пациенток с атрофическим вульвовагинитом в постменопаузе. Российский вестник акушера-гинеколога. 2020;20(3):62–67. DOI: 10.17116/rosakush20202003162.Кедрова А.Г. Профилактика атрофии влагалища после лечения опухолей органов женской репродуктивной системы. Опухоли женской репродуктивной системы. 2019;15(4):73–78. DOI: 10.17650/1994-4098-2019-15-4-73-78.Кедрова А.Г. Профилактика атрофии влагалища после лечения опухолей органов женской репродуктивной системы. Опухоли женской репродуктивной системы. 2019;15(4):73–78. DOI: 10.17650/1994-4098-2019-15-4-73-78.Capobianco G., Wenger J.M., Meloni G.B., Dessole M., Cherchi P.L., Dessole S. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch. Gynecol. Obstet. 2014;289(3):601–608. DOI: 10.1007/s00404-013-3030-6.Capobianco G., Wenger J.M., Meloni G.B., Dessole M., Cherchi P.L., Dessole S. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch. Gynecol. Obstet. 2014;289(3):601–608. DOI: 10.1007/s00404-013-3030-6.Di Mauro R., Cantarella G., Bernardini R., Di Rosa M., Barbagallo I., Distefano A. et al. The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Int. J. Mol. Sci. 2019;20:634. DOI: 10.3390/ijms20030634.Di Mauro R., Cantarella G., Bernardini R., Di Rosa M., Barbagallo I., Distefano A. et al. The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Int. J. Mol. Sci. 2019;20:634. DOI: 10.3390/ijms20030634.Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003;83:835–870. DOI: 10.1152/physrev.2003.83.3.835.Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003;83:835–870. DOI: 10.1152/physrev.2003.83.3.835.Vincent F. Mechanisms of cutaneous wound repair. In: Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F., Goldsmith L.A., Katz S.I. (eds) Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw Hill, 2003:236–246.Vincent F. Mechanisms of cutaneous wound repair. In: Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F., Goldsmith L.A., Katz S.I. (eds) Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw Hill, 2003:236–246.Kim H.S., Noh S.U., Han Y.W., Kim K.M., Kang H., Kim H.O. et al. Therapeutic Effects of topical application of ozone on acute cutaneous wound healing. J. Korean Med. Sci. 2009;24(3):368–374. DOI: 10.3346/jkms.2009.24.3.368.Kim H.S., Noh S.U., Han Y.W., Kim K.M., Kang H., Kim H.O. et al. Therapeutic Effects of topical application of ozone on acute cutaneous wound healing. J. Korean Med. Sci. 2009;24(3):368–374. DOI: 10.3346/jkms.2009.24.3.368.Valacchi G., Fortino V., Bocci V. The dual action of ozone on the skin. Br. J. Dermatol. 2005;153:1096–1100. DOI: 10.1111/j.1365-2133.2005.06939.x.Valacchi G., Fortino V., Bocci V. The dual action of ozone on the skin. Br. J. Dermatol. 2005;153:1096–1100. DOI: 10.1111/j.1365-2133.2005.06939.x.Janic B., Umstead T.M., Phelps D.S., Floros J. Modulatory effects of ozone on THP-1 cells in response to SP-A stimulation. Am. J. Physiol. Lung Cell Mol. Physiol. 2005;288:L317– L325. DOI: 10.1152/ajplung.00125.2004.Janic B., Umstead T.M., Phelps D.S., Floros J. Modulatory effects of ozone on THP-1 cells in response to SP-A stimulation. Am. J. Physiol. Lung Cell Mol. Physiol. 2005;288:L317– L325. DOI: 10.1152/ajplung.00125.2004.Fischer S.M. Is cyclooxygenase-2 important in skin carcinogenesis? J. Environ. Pathol. Toxicol. Oncol. 2002;21:183–191.Fischer S.M. Is cyclooxygenase-2 important in skin carcinogenesis? J. Environ. Pathol. Toxicol. Oncol. 2002;21:183–191.Valacchi G., Pagnin E., Corbacho A.M., Olano E., Davis P.A., Packer L. et al. In vivo ozone exposure induces antioxidant/ stress-related responses in murine lung and skin. Free Radic. Biol. Med. 2004;36(5):673–681. DOI: 10.1016/j.freeradbiomed.2003.12.005.Valacchi G., Pagnin E., Corbacho A.M., Olano E., Davis P.A., Packer L. et al. In vivo ozone exposure induces antioxidant/ stress-related responses in murine lung and skin. Free Radic. Biol. Med. 2004;36(5):673–681. DOI: 10.1016/j.freeradbiomed.2003.12.005.Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. DOI: 10.1097/GME.0b013e3182a122c2.Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. DOI: 10.1097/GME.0b013e3182a122c2.The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American menopause society. Menopause. 2017;24:728–753. DOI: 10.1097/GME.0000000000000921.The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American menopause society. Menopause. 2017;24:728–753. DOI: 10.1097/GME.0000000000000921.Phillips N.A., Bachmann G.A. Genitourinary syndrome of menopause: common problem, effective treatments. Cleve Clin. J. Med. 2018;85:390–398. DOI: 10.3949/ccjm.85a.15081.Phillips N.A., Bachmann G.A. Genitourinary syndrome of menopause: common problem, effective treatments. Cleve Clin. J. Med. 2018;85:390–398. DOI: 10.3949/ccjm.85a.15081.Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–126. DOI: 10.3109/13697137.2014.947254.Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–126. DOI: 10.3109/13697137.2014.947254.Клинические рекомендации. Менопауза и климактерическое состояние у женщин 2021. URL: https://geropharm.ru/uploads/file/menopauza-i-klimaktericheskoe-sostoyanie-ughenschiny-kr-2021.pdf [дата обращения: 29.03.2023].Клинические рекомендации. Менопауза и климактерическое состояние у женщин 2021. URL: https://geropharm.ru/uploads/file/menopauza-i-klimaktericheskoe-sostoyanie-ughenschiny-kr-2021.pdf [дата обращения: 29.03.2023].Jokar A., Davari T., Asadi N., Ahmadi F., Foruhari S. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial. Int. J. Community Based Nurs Midwifery. 2016;4(1):6978.Jokar A., Davari T., Asadi N., Ahmadi F., Foruhari S. Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial. Int. J. Community Based Nurs Midwifery. 2016;4(1):6978.Козлов П.В., Доброхотова Ю.Э., Ильина И.Ю. Современные подходы к медикаментозной коррекции генитоуринарного менопаузального синдрома. Лечебное дело. 2021;2:58–64. DOI: 10.24412/2071-5315-2021-12331.Козлов П.В., Доброхотова Ю.Э., Ильина И.Ю. Современные подходы к медикаментозной коррекции генитоуринарного менопаузального синдрома. Лечебное дело. 2021;2:58–64. DOI: 10.24412/2071-5315-2021-12331.Biehl C., Plotsker O., Mirkin S. A systematic review of efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453. DOI: 10.1097/GME.0000000000001221.Biehl C., Plotsker O., Mirkin S. A systematic review of efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453. DOI: 10.1097/GME.0000000000001221.Phillips N.A., Bachmann G.A. Genitourinary syndrome of menopause: Common problem, effective treatments. Cleve Clin. J. Med. 2018;85(5):390–398. DOI: 10.3949/ccjm.85a.15081.Phillips N.A., Bachmann G.A. Genitourinary syndrome of menopause: Common problem, effective treatments. Cleve Clin. J. Med. 2018;85(5):390–398. DOI: 10.3949/ccjm.85a.15081.Обоскалова Т.А., Лаврентьева И.В., Прохорова О.В., Воронцова А.В. Коррекция симптомов вагинальной атрофии при терапии агонистами гонадотропин-рилизинг-гормона. Доктор.ру. 2016;3(120):30–33.Обоскалова Т.А., Лаврентьева И.В., Прохорова О.В., Воронцова А.В. Коррекция симптомов вагинальной атрофии при терапии агонистами гонадотропин-рилизинг-гормона. Доктор.ру. 2016;3(120):30–33.Клинышкова Т.В., Самосудова И.Б., Миронова О.Н. Оценка цервикального скрининга при лечении вульвовагинальной атрофии в пери- и постменопаузе. Гинекология. 2016;18(6):32–35.Клинышкова Т.В., Самосудова И.Б., Миронова О.Н. Оценка цервикального скрининга при лечении вульвовагинальной атрофии в пери- и постменопаузе. Гинекология. 2016;18(6):32–35.Muecka A.O., Ruana X., Prasauskasc V., Grobc P., Ortmann O. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–147. DOI: 10.1080/13697137.2017.1421923.Muecka A.O., Ruana X., Prasauskasc V., Grobc P., Ortmann O. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–147. DOI: 10.1080/13697137.2017.1421923.Torky H.A., Taha A., Marie H., El-Desouky E., Raslan O., Moussa A.A. et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21(2):174–178. DOI: 10.1080/13697137.2017.1421924.Torky H.A., Taha A., Marie H., El-Desouky E., Raslan O., Moussa A.A. et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21(2):174–178. DOI: 10.1080/13697137.2017.1421924.Kingsberg S.A., Wysocki S., Magnus L., Krychman M.L. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex Med. 2013;10(7):1790–1799. DOI: 10.1111/jsm.12190.Kingsberg S.A., Wysocki S., Magnus L., Krychman M.L. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J. Sex Med. 2013;10(7):1790–1799. DOI: 10.1111/jsm.12190.Palacios S., Mejía A., Neyro J.L. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015;18:23–29. DOI: 10.3109/13697137.2015.1079100.Palacios S., Mejía A., Neyro J.L. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015;18:23–29. DOI: 10.3109/13697137.2015.1079100.Crandall C.J., Hovey K.M., Andrews C.A., Chlebowski R.T., Stefanick M.L., Lane D.S. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. DOI: 10.1097/GME.0000000000000956.Crandall C.J., Hovey K.M., Andrews C.A., Chlebowski R.T., Stefanick M.L., Lane D.S. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. DOI: 10.1097/GME.0000000000000956.Bachmann G., Santen R.J. Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). URL: https://uptodatefree.ir/topic.htm?path=treatment-of-genitourinary-syndrome-of-menopause-vulvovaginal-atrophy [дата обращения: 29.03.2023].Bachmann G., Santen R.J. Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). URL: https://uptodatefree.ir/topic.htm?path=treatment-of-genitourinary-syndrome-of-menopause-vulvovaginal-atrophy [дата обращения: 29.03.2023].Labrie F., Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al.ur É. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339– 1353. DOI: 10.1097/GME.0000000000001238.Labrie F., Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al.ur É. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339– 1353. DOI: 10.1097/GME.0000000000001238.Тихомирова Е.В., Балан В.Е., Фомина-Нилова О.С. Методы лечения генитоуринарного синдрома на современном этапе. Медицинский совет. 2020;(13):91–96. DOI: 10.21518/2079-701X-2020-13-91-96.Тихомирова Е.В., Балан В.Е., Фомина-Нилова О.С. Методы лечения генитоуринарного синдрома на современном этапе. Медицинский совет. 2020;(13):91–96. DOI: 10.21518/2079-701X-2020-13-91-96.Аполихина И.А., Рамазанова М.О. Первый российский опыт применения ND:YAG-лазера (неодимового лазера) для лечения симптомов генитоуринарного менопаузального синдрома. Акушерство и гинекология: новости, мнения, обучение. 2021;10(1):6–10. DOI: 10.33029/2303-9698-2022-10-1-6-10.Аполихина И.А., Рамазанова М.О. Первый российский опыт применения ND:YAG-лазера (неодимового лазера) для лечения симптомов генитоуринарного менопаузального синдрома. Акушерство и гинекология: новости, мнения, обучение. 2021;10(1):6–10. DOI: 10.33029/2303-9698-2022-10-1-6-10.Wańczyk-Baszak J., Woźniak S., Milejski B., Paszkowski T. Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency. Menopause Rev. 2018;17(4):180–184. DOI: 10.5114/pm.2018.81743.Wańczyk-Baszak J., Woźniak S., Milejski B., Paszkowski T. Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency. Menopause Rev. 2018;17(4):180–184. DOI: 10.5114/pm.2018.81743.Salvatore S., Athanasiou S., Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr. Opin. Obstet. Gynecol. 2015;27:504–508. DOI: 10.1097/GCO.0000000000000230.Salvatore S., Athanasiou S., Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr. Opin. Obstet. Gynecol. 2015;27:504–508. DOI: 10.1097/GCO.0000000000000230.Gambacciani M., Levancini M., Russo E., Vacca L., Simoncini T., Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21:148–152. DOI: 10.1080/13697137.2018.1436538.Gambacciani M., Levancini M., Russo E., Vacca L., Simoncini T., Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21:148–152. DOI: 10.1080/13697137.2018.1436538.Athanasiou S., Pitsouni E., Falagas M.E., Salvatore S., Grigoriadis T. CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas. 2017;104:24– 28. DOI: 10.1016/j.maturitas.2017.07.007.Athanasiou S., Pitsouni E., Falagas M.E., Salvatore S., Grigoriadis T. CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas. 2017;104:24– 28. DOI: 10.1016/j.maturitas.2017.07.007.Pitsouni E., Grigoriadis T., Falagas M.E., Salvatore S., Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78–88. DOI: 10.1016/j.maturitas.2017.06.029.Pitsouni E., Grigoriadis T., Falagas M.E., Salvatore S., Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78–88. DOI: 10.1016/j.maturitas.2017.06.029.Arroyo C. Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int. J. Womens Health. 2017;9:591–595. DOI: 10.2147/IJWH.S136857.Arroyo C. Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int. J. Womens Health. 2017;9:591–595. DOI: 10.2147/IJWH.S136857.Eder S.E. Early effect of fractional CO2 laser treatment in Post-menopausal women with vaginal atrophy. Laser Ther. 2018;27(1):41–47. DOI: 10.5978/islsm.18-OR-04.Eder S.E. Early effect of fractional CO2 laser treatment in Post-menopausal women with vaginal atrophy. Laser Ther. 2018;27(1):41–47. DOI: 10.5978/islsm.18-OR-04.Gordon C., Gonzales S., Krychman M.L. Rethinking the techno vagina: A case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423– 427. DOI: 10.1097/GME.0000000000001293.Gordon C., Gonzales S., Krychman M.L. Rethinking the techno vagina: A case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26(4):423– 427. DOI: 10.1097/GME.0000000000001293.Caruth J.C. Evaluation of the safety and efficacy of a novel radiofrequency device for vaginal treatment. Surg. Technol. Int. 2018;32:145–149.Caruth J.C. Evaluation of the safety and efficacy of a novel radiofrequency device for vaginal treatment. Surg. Technol. Int. 2018;32:145–149.Vicariotto F., Raichi M. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms. First experiences with a novel dynamic quadripolar device. Minerva Ginecol. 2016;68:225–236.Vicariotto F., Raichi M. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms. First experiences with a novel dynamic quadripolar device. Minerva Ginecol. 2016;68:225–236.Alinsod R.M. Temperature controlled radiofrequency for vulvovaginal laxity. Prime. 2015;3(4):16–21.Alinsod R.M. Temperature controlled radiofrequency for vulvovaginal laxity. Prime. 2015;3(4):16–21.Аполихина И.А., Уруймагова А.Т., Тетерина Т.А. Современные возможности и перспективы развития эстетической гинекологии. Медицинский оппонент. 2019;3(7):63–69.Аполихина И.А., Уруймагова А.Т., Тетерина Т.А. Современные возможности и перспективы развития эстетической гинекологии. Медицинский оппонент. 2019;3(7):63–69.

The authors declare that there are no conflicts of interest present.